Main Newsletter
Mastery Series
Therapy Series
 
Bookmark and Share | Print Article | Items for the Week Previous | All Articles This Week | Next
This article originally posted and appeared in  MedicationType 2 DiabetesGLP-1Issue 729GLP-1 Special Editions May 2014GLP-1 Special Editions June 2014

Chronic Twice-daily Exenatide Treatment on Beta Cell Function in New-onset T2DM

Improvements seen in peripheral insulin sensitivity and hepatic insulin extraction….

Advertisement

Researchers conducted a 24-week, randomized, double-blinded, placebo-controlled, multicenter study with 79 participants given an oral glucose tolerance test at baseline before starting treatment and after 24 weeks of treatment. Participants were asked to report to their clinical testing site in the morning after an overnight fast of 10-12 hours.

The results of the trial showed that all groups lost significant amounts of weight around 2-5 kilograms, but when compared to the placebo, 24-weeks of daily high or low doses reduced HbA1c and additionally, improved fasting and postprandial hyperglycemia as well. Exenatide was associated with an improved peripheral insulin sensitivity and hepatic insulin resistance index free of changes in weight. Plasma insulin levels and insulin secretion rates, however, during the oral glucose tolerance test did not differ before or after treatment with exenatide or placebo. Exenatide when given in the higher dose was associated with a significant improvement in beta cell sensitivity to glucose, and reduced hepatic insulin extraction. The P value was less than 0.05, labeling this study as statistically significant.

According to the results of this study, a patient with new onset type 2 diabetes given exenatide chronically will experience enhanced insulin secretion rates, and increased beta cell sensitivity to glucose. Although these improvements are seen in the beta cell function, the plasma insulin and C-peptide levels do not necessarily reflect so.

Practice Pearls:
  • When given exenatide chronically it enhances insulin secretion rates, and increases beta cell sensitivity to glucose
  • Improvements when giving exenatide chronically is seen in the beta cell function but does not reflect in the plasma insulin and C-peptide levels
  • Patients taking exenatide in this study also showed significant weight loss, around 2-5 kilograms.

Gastaldelli, Amalia, Robert G. Brodows, and David D'Alessio. "The Effect of Chronic Twice Daily Exenatide Treatment on β-cell Function in New Onset Type 2 Diabetes." Clin Endocrinol. 2014;80(4):545-553.  

Advertisement


 

Bookmark and Share | Print | Category | Home

This article originally posted 16 May, 2014 and appeared in  MedicationType 2 DiabetesGLP-1Issue 729GLP-1 Special Editions May 2014GLP-1 Special Editions June 2014

Past five issues: Issue 756 | Diabetes Clinical Mastery Series Issue 215 | SGLT-2 Inhibitors Special Edition November 2014 | Issue 755 | GLP-1 Special Editions November 2014 |

2014 Most Popular Articles:

Grapefruit Juice May Affect Insulin Resistance
Posted October 23, 2014
FDA Accepts Filing of NDA for Empagliflozin/Metformin Fixed-dose Combination
Posted October 23, 2014
What's Hiding in that Insulin Box?
Posted October 27, 2014
New SGLT2 Inhibitor Likely To Be Approved for Type 2 Diabetes
Posted November 14, 2014
Dietary Magnesium Intake's Role in Decreasing Metabolic Syndrome
Posted October 31, 2014
Handbook of Diabetes, 4th Ed., Excerpt #16: Diabetic Neuropathy
Posted November 02, 2014
Very Low Carbohydrate, Low Saturated Fat Diet for Type 2 Diabetes Management
Posted November 07, 2014
Exenatide a Noninsulin Addition for Patients Failing Basal Insulin
Posted October 23, 2014
New Approach Targets Type 2's Poorly Controlled With Metformin
Posted November 14, 2014
Interview with NuSirt CEO Joe Cook, Jr: Improving Metformin Treatment, Part 1
Posted November 02, 2014


Browse by Feature Writer & Article Category.
A. Lee Dellon, MD | Aaron I. Vinik, MD, PhD, FCP, MACP | Beverly Price | Charles W Martin, DD | Derek Lowe, PhD | Dr. Brian Jakes, Jr. | Dr. Fred Pescatore | Dr. Tom Burke, Ph.D | Eric S. Freedland | Evan D. Rosen | Ginger Kanzer-Lewis | Greg Milliger | Kristina Sandstedt | Laura Plunkett | Leonard Lipson, M.A. | Louis H. Philipson | Maria Emanuel Ryan, DDS, PhD | Marilyn Porter, RD, CDE | Melissa Diane Smith | Michael R. Cohen, RPh, MS, ScD, FASHP | Paul Chous, M.A., OD | Philip A. Wood PhD | R. Keith Campbell, Professor, B.Pharm, MBA, CDE | Richard K. Bernstein, MD | Sheri R. Colberg PhD | Sherri Shafer | Stanley Schwartz, MD, FACP, FACE | Steve Pohlit | Steven V. Edelman, M.D. | Timothy S. Hollingshead |

Cast Your Vote
If the U.S. Affordable Care Act is reversed in the new congress, what impact will that have on your patients?
CME/CE of the Week
Warren Joseph, DPM, FIDSA

Category: Wound Care
Credits: .75



Search Articles On Diabetes In Control